The FDA on September 20, 2021 granted accelerated approval to TIVDAK®, a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
TIVDAK® is a product of Seagen Inc.
Bottom Ad
Advertisement
Subscribe
